Keynote Presentation: Day 2 - Richard Pötter
LDR, HDR, or PDR - Crossroads - Janusz Skowronek
Why Choose Brachytherapy and Not EBRT?
- Mitchell Kamrava

Is LDR Brachytherapy Still an Option for Developing Countries? - André-Guy Martin
The Role of HDR Monotherapy for Intermediate-/
High-Risk Prostate Cancer Patients - John K. Hayes, Jr.

The Role of HDR Boost for High-Risk Prostate Cancer Patients - Ferrán Guedea
Prostate Cancer Results Study Group 2014 - Results Comparing Treatment of Prostate Cancer
- Peter Grimm

Panel Discussion

If you are viewing this program on a mobile device, please click here.